8-K: electroCore Reports Record 2025 Sales, CEO Goldberger Retires

electroCore, Inc. announced record full year 2025 net sales of $32.0 million, a 27% increase, alongside the retirement of CEO Dan Goldberger and new executive appointments.

Summary

• Record full year 2025 net sales reached $32.0 million, marking a 27% increase from $25.2 million in 2024.
• U.S. prescription business grew by 25% annually, while general wellness sales surged by 97%.
• Gross profit increased by $6.4 million to $27.8 million, with gross margin improving to 87% in 2025 from 85% in 2024.
• GAAP net loss for 2025 was $14.0 million, an increase from $11.9 million in 2024.
• Adjusted EBITDA net loss improved slightly to $8.7 million in 2025 from $9.0 million in 2024.
• Cash, cash equivalents, and marketable securities totaled $11.6 million as of December 31, 2025.
• Dan Goldberger will retire as Chief Executive Officer effective April 1, 2026.
• Joshua Lev, current CFO, will assume the role of interim President.
• Michael Fox has been hired as Chief Operating Officer, joining in April.
• The company provided full year 2026 revenue guidance of approximately 30% annual growth.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by strong revenue growth and improved gross margins, alongside a slight improvement in adjusted EBITDA. However, the increasing GAAP net loss and declining cash position, coupled with significant management changes, introduce elements of caution.

Positives

• Record full year 2025 net sales of $32.0 million, a 27% increase over 2024.
• Strong growth in U.S. prescription business (25% annual growth) and general wellness sales (97% increase).
• Improved gross margin to 87% in 2025 from 85% in 2024, indicating better product mix and efficiency.
• Adjusted EBITDA net loss improved to $8.7 million in 2025 from $9.0 million in 2024, suggesting better operational efficiency excluding certain non-GAAP adjustments.
• Guidance for approximately 30% annual revenue growth in 2026 indicates continued positive momentum.
• Hiring Michael Fox as Chief Operating Officer is expected to strengthen the sales management team and drive revenue growth.

Negatives

• GAAP net loss increased to $14.0 million in 2025 from $11.9 million in 2024.
• Net loss per share increased to $1.65 in 2025 from $1.59 in 2024.
• Total operating expenses increased significantly to $40.9 million in 2025 from $33.6 million in 2024, primarily due to increased SG&A.
• Cash, cash equivalents, and marketable securities decreased to $11.6 million at December 31, 2025, from $12.2 million at December 31, 2024.
• Total stockholders' equity moved into a deficit of $(1.709) million at December 31, 2025, from $7.544 million at December 31, 2024.
• TAC-STIM sales decreased by 65% from $1.197 million in 2024 to $422k in 2025.
• Other expense increased by $1.0 million, including a $0.5 million change in estimated liability for the NeuroMetrix acquisition CVR and increased interest expense.

Risks

• Ability to raise additional funding needed to continue business and product development plans.
• Inherent uncertainties associated with developing new products or technologies.
• Ability to commercialize gammaCore, TAC-STIM, Truvaga, and Quell products.
• Impact of inflation and currency fluctuations on financial performance.
• Competition in the bioelectronic technology industry.
• Overall economic and market conditions affecting business prospects.

Future Outlook

The company projects approximately 30% annual revenue growth for the full year 2026 over 2025, driven by continued momentum in its bioelectronic technology products.

Management Comments

• "On behalf of the Board of Directors, I want to thank Dan for his dedicated leadership and many contributions to the Company’s growth. We are grateful and fortunate that he will continue advising the Company as a consultant for the next year." Dr. Thomas Errico, Chairman of the Board of Directors.
• "I am honored to assume the role of Interim President in addition to my responsibilities as CFO. I would like to extend our sincere appreciation to Dan for his leadership and the foundation he leaves behind. We are experiencing robust momentum, and I believe we are very well positioned to define the bioelectronic technology category and remain very optimistic about our prospects for 2026 and beyond." Joshua Lev, CFO and interim President.

Industry Context

StockSavvy.ai notes that electroCore operates in the growing bioelectronic technology sector, focusing on non-invasive neuromodulation for chronic pain and general wellness. The strong growth in U.S. prescription and general wellness sales suggests increasing market acceptance for its nVNS products like gammaCore and Truvaga, aligning with broader trends towards non-pharmacological treatment options. The decline in TAC-STIM sales, however, indicates potential competitive pressures or shifting market preferences within specific product lines, while the overall revenue growth and positive outlook for 2026 position the company to potentially expand its market share in this innovative space.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. StockSavvy.ai notes that without direct comparisons to peers in the non-invasive neuromodulation or bioelectronic technology space, it is challenging to definitively assess electroCore's performance against industry standards.
• However, the 87% gross margin is generally strong for a medical device company, suggesting efficient production and pricing power for its specialized products.
• The company's 27% revenue growth in 2025 and 30% projected growth for 2026 are robust, but their sustainability and market penetration relative to competitors would require further analysis of market share and product pipeline.

Management Changes

Legal Proceedings

• Legal fees associated with stockholders litigation and intellectual litigation were incurred, contributing to increased general and administrative expenses.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and positive 2026 guidance, but diluted by increased net loss per share and declining equity. Management changes introduce uncertainty but also potential for strategic renewal.
• Employees: Changes in executive leadership (CEO retirement, new COO, interim President) may impact company culture and strategic direction.
• Customers: Continued product development (gammaCore Emerald, mobile app) and strengthened sales management (new COO) could lead to improved product offerings and customer service.
• Creditors: The decline in total cash and shift to a stockholders' deficit could be a point of concern, though adjusted EBITDA improved. The mention of interest associated with term debt financing with Avenue Venture Opportunities Fund II, L.P. indicates existing debt obligations.

Next Steps

• Host a conference call and webcast on March 19, 2026, at 4:30 PM EDT to discuss financial results and organizational changes.
• Dan Goldberger will continue advising the company as a consultant for the next year.
• Joshua Lev will assume the interim President role effective April 1, 2026.
• Michael Fox will join as Chief Operating Officer in April 2026.
• Continue development costs associated with gammaCore Emerald and next-generation mobile application.
• Pursue business and product development plans, which may require additional funding.

Key Dates

Recommendation

While electroCore demonstrated strong revenue growth and improved gross margins in 2025, along with positive 2026 guidance, the increasing GAAP net loss and a shift to a stockholders' deficit are significant concerns. The executive leadership transition, including the CEO's retirement and new appointments, introduces both potential for strategic renewal and a degree of uncertainty. Given the mixed financial signals and leadership changes, a 'hold' recommendation is appropriate for seasoned investors to observe how the new leadership executes on the growth strategy and addresses profitability and cash flow challenges.

Keywords

bioelectronic technology, nVNS, gammaCore, Truvaga, Quell Fibromyalgia, TAC-STIM, neuromodulation, financial results, revenue growth, CEO retirement, executive changes, SEC filing, ECOR, medical devices, pain management, general wellness